These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26844490)

  • 1. Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy.
    Geng Y; Wang X; Lu X; Wu X; Xu N; Han L; Xu J
    Medicine (Baltimore); 2016 Feb; 95(5):e2657. PubMed ID: 26844490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.
    Yang HC; Chen CL; Shen YC; Peng CY; Liu CJ; Tseng TC; Su TH; Chuang WL; Yu ML; Dai CY; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2013 Mar; 57(3):934-43. PubMed ID: 23112104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion.
    Nie H; Evans AA; London WT; Block TM; Ren XD
    J Hepatol; 2012 Apr; 56(4):795-802. PubMed ID: 22173170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment.
    Zampino R; Marrone A; Cirillo G; del Giudice EM; Utili R; Karayiannis P; Liang TJ; Ruggiero G
    J Viral Hepat; 2002 May; 9(3):183-8. PubMed ID: 12010505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.
    Kamijo N; Matsumoto A; Umemura T; Shibata S; Ichikawa Y; Kimura T; Komatsu M; Tanaka E
    World J Gastroenterol; 2015 Jan; 21(2):541-8. PubMed ID: 25593470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of hepatitis B virus precore and core promoter variants in Korean patients with chronic hepatitis B.
    Yim SY; Um SH; Young Jung J; Kim TH; Kim JD; Keum B; Seo YS; Yim HJ; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Clin Gastroenterol; 2015 Jan; 49(1):61-8. PubMed ID: 24406435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    J Med Virol; 2003 Jul; 70(3):355-60. PubMed ID: 12766997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.
    Chen RY; Bowden S; Desmond PV; Dean J; Locarnini SA
    J Gastroenterol Hepatol; 2003 Jun; 18(6):630-7. PubMed ID: 12753143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea.
    Yoo BC; Park JW; Kim HJ; Lee DH; Cha YJ; Park SM
    J Hepatol; 2003 Jan; 38(1):98-103. PubMed ID: 12480566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-α-2a treatment in child patients.
    Yang J; Yang G; He H; Ning L; Liu Z; Fu Q; Chen H; Deng H; Wang Z; Luo K
    Antivir Ther; 2018; 23(7):567-574. PubMed ID: 30095435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B.
    Chuaypen N; Payungporn S; Poovorawan K; Chotiyaputta W; Piratvisuth T; Tangkijvanich P
    Virus Genes; 2019 Oct; 55(5):610-618. PubMed ID: 31359359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection].
    Kim HJ; Yoo BC
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):149-56. PubMed ID: 12499800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
    Cho SW; Hahm KB; Kim JH
    Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection.
    Marrone A; Zampino R; Luongo G; Utili R; Karayiannis P; Ruggiero G
    Intervirology; 2003; 46(4):222-6. PubMed ID: 12931030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection.
    Zhong YW; Di FL; Liu C; Zhang XC; Bi JF; Li YL; Wu SQ; Dong H; Liu LM; He J; Shi YM; Zhang HF; Zhang M
    Clin Microbiol Infect; 2016 Apr; 22(4):379.e1-379.e8. PubMed ID: 26577140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B.
    Shindo M; Hamada K; Koya S; Sokawa Y; Okuno T
    Am J Gastroenterol; 1999 Aug; 94(8):2237-45. PubMed ID: 10445556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
    Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
    J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B].
    Yoo BC; Kim HJ; Do JH; Park SM
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):381-8. PubMed ID: 12506242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.